Reciprocally, AR inhibition in PTEN-null prostate cancer caused AKT activation due to destabilization of the AKT phosphatase PHLPP, which resulted from reduced AR-targeted expression of FKBP5, a chaperone protein for PHLPP. This evidence concerns the gene AR and prostate carcinoma.